Last reviewed · How we verify
[14C]-AQX-1125 IV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-AQX-1125 IV ([14C]-AQX-1125 IV) — Aquinox Pharmaceuticals (Canada) Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-AQX-1125 IV TARGET | [14C]-AQX-1125 IV | Aquinox Pharmaceuticals (Canada) Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-AQX-1125 IV CI watch — RSS
- [14C]-AQX-1125 IV CI watch — Atom
- [14C]-AQX-1125 IV CI watch — JSON
- [14C]-AQX-1125 IV alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-AQX-1125 IV — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-aqx-1125-iv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab